Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Baxter
Accenture
Teva
Harvard Business School
McKesson
US Department of Justice
Citi

Generated: October 21, 2018

DrugPatentWatch Database Preview

VIOXX Drug Profile

« Back to Dashboard

When do Vioxx patents expire, and when can generic versions of Vioxx launch?

Vioxx is a drug marketed by Merck and is included in two NDAs.

The generic ingredient in VIOXX is rofecoxib. There are two drug master file entries for this compound. Additional details are available on the rofecoxib profile page.

Drug patent expirations by year for VIOXX
Synonyms for VIOXX
011R907
0QTW8Z7MCR
162011-90-7
186912-82-3
2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-
2(5H)-Furanone, 4-[4-(methyl-sulfonyl)phenyl]-3-phenyl-
2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-
3-(4-methanesulfonyl-phenyl)-2-phenyl-2-buten-4-olide
3-(4-methanesulfonylphenyl)-2-phenyl-2-buten-4-olide
3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one
3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
3-Phenyl-4-(4-(Methylsulfonyl)Phenyl)-2-(5H)-Furanone
3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone
3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone
4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone
4-(4-(Methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
4-(4-METHANESULFONYL-PHENYL)-3-PHENYL-5H-FURAN-2-ONE
4-(4-methanesulfonylphenyl)-3-phenyl-2,5-dihydrofuran-2-one
4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one
4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone
4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
544684-93-7
A810324
AB00052090_09
AB00052090_10
AB00052090-06
AB00052090-08
AB0012045
AB07701
AC-28318
AC1L1JL6
AJ-08299
AK-60971
AKOS000280931
AN-25306
ANW-71936
AOB6956
BDBM22369
BIDD:GT0399
Bio-0094
BRD-K21733600-001-02-6
BSPBio_002705
C07590
C17H14O4S
Cahill May Roberts brand of rofecoxib
CAS-162011-90-7
CCG-40253
CCRIS 8967
ceeoxx
Ceeoxx (TN)
Ceoxx
Ceoxx (TN)
CHEBI:8887
CHEMBL122
cMAP_000024
CPD000466331
CS-0997
D00568
D05VLS
DB00533
DivK1c_006765
DR001346
DSSTox_CID_3567
DSSTox_GSID_23567
DSSTox_RID_77084
DTXSID2023567
EBD34785
EX-A708
FT-0081390
FT-0631192
GTPL2893
HE230410
HE320865
HMS1922H11
HMS2051G16
HMS2089H20
HMS2093E04
HMS2232G21
HMS3371P11
HMS3393G16
HMS3651F16
HSDB 7262
HY-17372
I01-1042
J10420
Jsp003237
K-5064
KBio1_001709
KBio2_000559
KBio2_002345
KBio2_003127
KBio2_004913
KBio2_005695
KBio2_007481
KBio3_002205
KBio3_002825
KBioGR_001242
KBioGR_002345
KBioSS_000559
KBioSS_002348
KS-00000XKS
KS-1107
L000912
LS-70511
MCULE-4806636118
Merck brand of rofecoxib
Merck Frosst brandof rofecoxib
Merck Sharp & Dhome brand of rofecoxib
MFCD00935806
MK 0966
MK 0996
MK 966
MK 996
MK-0966
MK-966
MK0966
MK966
MLS000759440
MLS001165770
MLS001195623
MLS001424113
MLS006010091
MolPort-000-883-878
MolPort-006-817-786
MSD brand of rofecoxib
NC00132
NCGC00095118-01
NCGC00095118-02
NCGC00095118-03
NCGC00095118-04
NCGC00095118-05
NCI60_041175
NSC-720256
NSC-758705
NSC720256
NSC758705
Pharmakon1600-01504235
PubChem15028
Q-201676
R0206
refecoxib
rofecoxib
Rofecoxib (JAN/USAN/INN)
Rofecoxib (Vioxx)
Rofecoxib [USAN:INN:BAN]
rofecoxibum
RT-016235
RZJQGNCSTQAWON-UHFFFAOYSA-N
s3043
SAM001246617
SBI-0206774.P001
SC-17320
SCHEMBL3050
SMR000466331
SPBio_000492
SpecPlus_000669
Spectrum_000119
SPECTRUM1504235
Spectrum2_000446
Spectrum3_001153
Spectrum4_000631
Spectrum5_001598
ST2410970
STK635144
Tox21_111430
TRM-201
UNII-0QTW8Z7MCR
VA11689
Vioxx (TN)
Vioxx (trademark)
Vioxx Dolor
Vioxx-d5 (Major)
Vioxx; 4-[4-(Methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
ZB000656
ZINC7455

US Patents and Regulatory Information for VIOXX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck VIOXX rofecoxib SUSPENSION;ORAL 021052-001 May 20, 1999 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib TABLET;ORAL 021042-002 May 20, 1999 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib SUSPENSION;ORAL 021052-002 May 20, 1999 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib TABLET;ORAL 021042-001 May 20, 1999 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib TABLET;ORAL 021042-003 Feb 25, 2000 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for VIOXX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck VIOXX rofecoxib SUSPENSION;ORAL 021052-002 May 20, 1999 ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib TABLET;ORAL 021042-003 Feb 25, 2000 ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib TABLET;ORAL 021042-002 May 20, 1999 ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib TABLET;ORAL 021042-002 May 20, 1999 ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib TABLET;ORAL 021042-003 Feb 25, 2000 ➤ Sign Up ➤ Sign Up
Merck VIOXX rofecoxib SUSPENSION;ORAL 021052-001 May 20, 1999 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Baxter
Accenture
Teva
Harvard Business School
McKesson
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.